This systematic review summarizes the outcome reporting standards in Dupuytren’s disease treatment research. A search of Ovid Medline, Ovid Embase, and CINAHL was conducted. Randomized controlled trials, cohort studies, and case series published between 1997 and 2017, investigating treatment of Dupuytren’s disease with fasciectomy, fasciotomy, or collagenase, were eligible for inclusion. Range of motion was the most commonly reported outcome, appearing in 77% of included studies. Outcomes, such as range of motion, recurrence, and clinical success, were frequently defined, however many different definitions were used. We identified 37 unique measurement methods for range of motion, 28 for recurrence, and 25 for clinical success. Most outcomes were assessed at multiple time points, and only a few studies reported results according to established clinical significance thresholds. Development of a core outcome set will help standardize outcome reporting, and ensure future research in this field is relevant, interpretable, and amenable to systematic review and/or meta-analysis.
AbeYRokkakuTOfuchiSTokunagaSTakahashiKMoriyaH. Surgery for Dupuytren’s disease in Japanese patients and a new preoperative classification. J Hand Surg Br. 2004, 29: 235–9.
2.
AlbertonFCorainMGarofanoA, et al.Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren contracture: report of 40 cases. Musculoskelet Surg. 201498: 225–32.
3.
AnwarMUAl GhazalSKBoomeRS. Results of surgical treatment of Dupuytren’s disease in women: a review of 109 consecutive patients. J Hand Surg Am. 2007, 32: 1423–8.
4.
AtroshiINordenskjoldJLauritzsonAAhlgrenEWaldauJWaldenM. Collagenase treatment of Dupuytren’s contracture using a modified injection method: a prospective cohort study of skin tears in 164 hands, including short-term outcomes. Acta Orthop. 2015, 86: 310–5.
5.
AtroshiIStrandbergELauritzsonAAhlgrenEWaldenM. Costs for collagenase injections compared with fasciectomy in the treatment of Dupuytren’s contracture: a retrospective cohort study. BMJ Open. 2014, 4: e004166.
6.
BainbridgeCDahlinLBSzczypaPPCappelleriJCGuerinDGerberRA. Current trends in the surgical management of Dupuytren’s disease in Europe: an analysis of patient charts. Eur Orthop Traumatol. 2012, 3: 31–41.
7.
BallCPrattALNanchahalJ. Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice. BMC Musculoskelet Disord. 2013, 14: 131.
8.
BearBJPeimerCAKaplanFTDKaufmanGJTursiJPSmithT. Treatment of recurrent Dupuytren contracture in joints previously effectively treated with collagenase Clostridium histolyticum. J Hand Surg Am. 2017, 42: 391.e1–8.
9.
BismilQBismilMBismilA, et al.The development of one-stop wide-awake Dupuytren’s fasciectomy service: a retrospective review. JRSM Short Rep. 20123: 48.
10.
BowlingA. Mode of questionnaire administration can have serious effects on data quality. J Public Health (Bangkok). 2005, 27: 281–91.
11.
DahlinLBBainbridgeCSzczypaPPCappelleriJCGuerinDGerberRA. Current trends in the surgical management of Dupuytren’s disease in Europe: the surgeon's perspective. Eur Orthop Traumatol. 2012, 3: 25–30.
12.
DegreefIBoogmansTSteenoPDe SmetL. Surgical outcome of Dupuytren’s disease – No higher self-reported recurrence after segmental fasciectomy. Eur J Plast Surg. 2009, 32: 185–8.
DiasJBainbridgeCLeclercqC, et al.Surgical management of Dupuytren’s contracture in Europe: regional analysis of a surgeon survey and patient chart review. Int J Clin Pract. 201367: 271–81.
15.
DiasJJBraybrookeJ. Dupuytren’s contracture: an audit of the outcomes of surgery. J Hand Surg Am. 2006, 31: 514–21.
16.
DongaPDeKovenMKaplanTTursiJPLeeWC. Costs of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture. Am J Pharm Benefits. 2015, 7: 24–31.
17.
DuthieRAChesneyRB. Percutaneous fasciotomy for Dupuytren’s contracture. J Hand Surg Am. 1997, 22B: 521–2.
18.
EckerdalDNivestamADahlinLB. Surgical treatment of Dupuytren’s disease – outcome and health economy in relation to smoking and diabetes. BMC Musculoskelet Disord. 2014, 15: 117.
19.
Edmunds I, Chein C. A new surgical approach to Dupuytren's disease. J Hand Surg Eur. 2011, 36: 485–489.
20.
EngstrandCBorenLLiedbergGM. Evaluation of activity limitation and digital extension in Dupuytren’s contracture three months after fasciectomy and hand therapy interventions. J Hand Ther. 2009, 22: 21–7.
21.
EngstrandCKreversBKvistJ. Factors affecting functional recovery after surgery and hand therapy in patients with Dupuytren’s disease. J Hand Ther. 2015, 28: 255–60.
22.
EngstrandCKreversBNylanderGKvistJ. Hand function and quality of life before and after fasciectomy for Dupuytren contracture. J Hand Surg Am. 2014, 39: 1333.
23.
GastonRGLarsenSEPessGM, et al.The efficacy and safety of concurrent collagenase Clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective, multicenter study. J Hand Surg Am. 201540: 1963–71.
24.
GelmanSSchlenkerRBachouraA, et al.Minimally invasive partial fasciectomy for Dupuytren’s contractures. Hand (NY). 20127: 364–9.
25.
GilpinDColemanSHallSHoustonAKarraschJJonesN. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am. 2010, 35: 2027.
26.
GrandizioLCAkoonAHeimbachJGrahamJKlenaJC. The use of residual collagenase for single digits with multiple-joint Dupuytren contractures. J Hand Surg Am. 2017, 42: 472.e1–6.
27.
HallPNFitzgeraldASterneGDLoganAM. Skin replacement in Dupuytren’s disease. J Hand Surg (Edinburgh, Lothian). 1997, 22: 193–7.
28.
HardenRNBruehlSStanton-HicksMWilsonPR. Proposed new diagnostic criteria for complex regional pain syndrome. Pain Med. 2007, 8: 326–31.
29.
HerreraFABenhaimPSulimanARoostaeianJAzariKMitchellS. Cost comparison of open fasciectomy versus percutaneous needle aponeurotomy for treatment of Dupuytren contracture. Ann Plast Surg. 2013, 70: 454–6.
30.
HirataHTanakaKSakaiAKakinokiRIkegamiHTateishiN. Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren’s contracture in non-Caucasian Japanese patients (CORD-J Study): the first clinical trial in a non-Caucasian population. J Hand Surg Eur. 2017, 42: 30–40.
31.
HuisstedeBMGladdinesSRandsdorpMSKoesBW. Effectiveness of conservative, surgical, and postsurgical interventions for trigger finger, Dupuytren disease, and de Quervain disease: a systematic review. Arch Phys Med Rehabil. 2018, 99: 1635–49.e21.
32.
HurstLCBadalamenteMAHentzVR, et al.Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009361: 968–79.
33.
KanHJVerrijpFWHuisstedeBMHoviusSEvan NieuwenhovenCASellesRW. The consequences of different definitions for recurrence of Dupuytren’s disease. J Plast Reconstr Aesthetic Surg. 2013, 66: 95–103.
34.
KaplanFTDBadalamenteMAHurstLCMerrellGAPahkR. Delayed manipulation after collagenase Clostridium histolyticum injection for Dupuytren contracture. Hand (NY). 2015, 10: 578–82.
35.
LiberatiAAltmanDGTetzlaffJ, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 20096: e1000100.
36.
LipmanMDCarstensenSEDealDN. Trends in the treatment of Dupuytren disease in the United States between 2007 and 2014. Hand (NY). 2017, 12: 13–20.
MedjoubKJawadA. The use of multiple needle fasciotomy in Dupuytren disease: retrospective observational study of outcome and patient satisfaction. Ann Plast Surg. 2014, 72: 417–22.
39.
MehtaSBelcherHJCR. A single-centre cost comparison analysis of collagenase injection versus surgical fasciectomy for Dupuytren’s contracture of the hand. J Plast Reconstr Aesthetic Surg. 2014, 67: 368–72.
40.
MowakketSKarpinskiMGalloL, et al.Reporting time horizons in randomized controlled trials in plastic surgery: a systematic review. Plast Reconstr Surg. 2018142: 947e–57e.
41.
MuppavarapuRCWatersMJLeibmanMIBelskyMRRuchelsmanDE. Clinical outcomes following collagenase injections compared to fasciectomy in the treatment of Dupuytren’s contracture. Hand (NY). 2015, 10: 260–5.
42.
OdinssonABrenneLELurieTBFinsenV. Dupuytren’s contracture. The safety and efficacy of collagenase treatment. J Hand Surg Asian-Pacific Vol. 2016, 21: 187–92.
43.
PeimerCAMcGoldrickCAFioreGJ. Nonsurgical treatment of Dupuytren’s contracture: 1-year US post-marketing safety data for collagenase Clostridium histolyticum. Hand (NY). 2012, 7: 143–6.
44.
PrattALBallC. What are we measuring? A critique of range of motion methods currently in use for Dupuytren’s disease and recommendations for practice. BMC Musculoskelet Disord. 2016, 17: 20.
45.
PrattALByrneG. The lived experience of Dupuytren’s disease of the hand. J Clin Nurs. 2009, 18: 1793–802.
46.
RahrLSondergaardPBisgaardTBaad-HansenT. Percutaneous needle fasciotomy for primary Dupuytren’s contracture. J Hand Surg Eur. 2011, 36: 548–52.
47.
RodriguesJNBeckerGWBallC, et al.Surgery for Dupuytren’s contracture of the fingers. Cochrane Database Syst Rev. 201512: CD010143.
48.
RodriguesJNZhangWScammellBE, et al.Functional outcome and complications following surgery for Dupuytren’s disease: a multi-centre cross-sectional study. J Hand Surg Eur. 201742: 7–17.
49.
RoyNSharmaDMirzaAHFahmyN. Fasciectomy and conservative full thickness skin grafting in Dupuytren’s contracture. The fish technique. Acta Orthop Belg. 2006, 72: 678–82.
Sanjuan-CerveroRCarrera-HuesoFJVazquez-FerreiroPFikri-BenbrahimNFranco-FerrandoNPeimerCA. Pain associated with treatment of Dupuytren contracture with collagenase Clostridium histolyticum. J Hand Surg Am. 2017, 42: e109–14.
52.
Sanjuan-CerveroRFranco FerrandoNPoquet JornetJ. Use of resources and costs associated with the treatment of Dupuytren’s contracture at an orthopedics and traumatology surgery department in Denia (Spain): collagenase Clostridium hystolyticum versus subtotal fasciectomy. BMC Musculoskelet Disord. 2013, 14: 293.
53.
SkoffHD. The surgical treatment of Dupuytren’s contracture: a synthesis of techniques. Plast Reconstr Surg. 2004, 113: 540–4.
54.
SkovSTBisgaardTSondergaardPLangeJ. Injectable collagenase versus percutaneous needle fasciotomy for Dupuytren contracture in proximal interphalangeal joints: a randomized controlled trial. J Hand Surg Am. 2017, 42: 321–8.e3.
55.
StrombergJIbsen-SorensenAFridenJ. Comparison of treatment outcome after collagenase and needle fasciotomy for Dupuytren contracture: a randomized, single-blinded, clinical trial with a 1-year follow-up. J Hand Surg Am. 2016, 41: 873–80.
56.
SyedAMMcfarlaneJChesterTPowersDSiblyFTalbot-SmithA. Clinical efficacy and cost-effectiveness of Clostridium histolyticum collagenase injections in a subpopulation of Dupuytren’s contracture patients. Eur Orthop Traumatol. 2014, 5: 311–6.
57.
TerryMJSueGRGoldbergCNarayanD. Hueston revisited: use of acellular dermal matrix following fasciectomy for the treatment of Dupuytren’s disease. Ann Plast Surg. 2014, 73(Suppl 2): S178–80.
58.
ToppiJTTrompfLSmollNR, et al.Dupuytren’s contracture: an analysis of outcomes of percutaneous needle fasciotomy versus open fasciectomy. ANZ J Surg. 201585: 639–43.
59.
van RijssenALGerbrandyFSJTer LindenHKlipHWerkerPMN. A comparison of the direct outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytren’s disease: a 6-week follow-up study. J Hand Surg Am. 2006, 31: 717–25.
60.
VerheydenJR. Early outcomes of a sequential series of 144 patients with Dupuytren’s contracture treated by collagenase injection using an increased dose, multi-cord technique. J Hand Surg Eur. 2015, 40: 133–40.
61.
VerstrekenFDegreefIDecramerA, et al.Effectiveness and safety of collagenase Clostridium histolyticum in Dupuytren’s disease: an observational study in Belgium. Acta Orthop Belg. 201682: 397–404.
62.
WadeRIgaliLFigusA. Skin involvement in Dupuytren’s disease. J Hand Surg Eur. 2016, 41: 600–8.
63.
WarwickDArnerMPajardiG, et al.Collagenase Clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. J Hand Surg Eur. 201540: 124–32.
64.
WarwickDJGrahamDWorsleyP. New insights into the immediate outcome of collagenase injections for Dupuytren’s contracture. J Hand Surg Eur. 2016, 41: 583–8.
65.
WebbJAStothardJ. Cost minimisation using clinic-based treatment for common hand conditions—a prospective economic analysis. Ann R Coll Surg Engl. 2009, 91: 135–9.
66.
WerkerPMNPessGMvan RijssenALDenklerK. Correction of contracture and recurrence rates of Dupuytren contracture following invasive treatment: the importance of clear definitions. J Hand Surg Am. 2012, 37: 2095–105.e7.
67.
WhiteJWKangS-NNancooTFloydDKambhampatiSBSMcGroutherDA. Management of severe Dupuytren’s contracture of the proximal interphalangeal joint with use of a central slip facilitation device. J Hand Surg Eur. 2012, 37: 728–32.
68.
WilliamsonPRAltmanDGBagleyH, et al.The COMET Handbook: version 1.0. Trials. 201718: 280.
69.
WitthautJJonesGSkrepnikNKushnerHHoustonALindauTR. Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies. J Hand Surg Am. 2013, 38: 2–11.
70.
ZhouCHoviusSERSlijperHP, et al.Collagenase Clostridium histolyticum versus limited fasciectomy for Dupuytren’s contracture: outcomes from a multicenter propensity score matched study. Plast Reconstr Surg. 2015136: 87–97.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
